Datapharm has announced its expansion into the United States through a new partnership with phactMI.

The collaboration aims to improve the quality and accessibility of medicines information for healthcare professionals (HCPs) and patients across the US via the phactMI search tool, The Drug Information Database.

Datapharm operates the electronic medicines compendium (emc), a trusted online resource that attracts over 85 million visits globally each year. The emc hosts content from more than 320 global pharmaceutical companies and provides up-to-date information on medicines licensed in the UK.

Meanwhile, phactMI, a collaboration of pharmaceutical companies in the US, is dedicated to transparency in medical information.

“This partnership marks a significant milestone in our mission to support HCPs in delivering informed and effective patient care globally,” said Rich Cooper, CEO of Datapharm. “We are excited to build and strengthen our relationship with phactMI, combining our expertise to offer US HCPs an unmatched medicines information resource.”

Jon Stelzmiller, CEO of phactMI, echoed the sentiment, stating “phactMI is proud to support this innovative collaboration. Datapharm is uniquely positioned for this role as a specialist tech provider in medicines information.

“By integrating Datapharm’s technology with our platform, we will accelerate our goal of ensuring HCPs have access to comprehensive and accessible medicines information across the United States.”

The agreement between Datapharm and phactMI makes Datapharm’s cutting-edge search technology available to HCPs and patients across the US through phactMI.
This collaboration represents a major step forward in the global dissemination of accurate and accessible medicines information.

Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical trials.

Aspyre Lung simplifies the detection of non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood using a streamlined four-step workflow.

The partnership aims to support global clinical trials through innovative genomic services. CellCarta will initially set up and validate Aspyre Lung in its European laboratories, followed by its US-based laboratories.

Customers will benefit from revolutionary services using both liquid and tissue biopsy samples. This will help accelerate and facilitate rapid and reliable clinical trial enrolment.

“We are extremely pleased to enter into this strategic partnership with CellCarta,” said Biofidelity Co-Founder and CEO Barnaby Balmforth, PhD. “Partnering with CellCarta to make clinical trial enrolment faster and more efficient utilising Simplified Genomic Profiling (SGP) via Aspyre Lung moves us significantly forward toward fulfilling our mission.”

CellCarta CEO Dusty Tenney expressed excitement about the partnership. “CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry,” he said.

The partnership provides non-exclusive rights to utilise Aspyre Lung for clinical trials globally. This collaboration aims to enhance precision medicine with specialised laboratory services.

Biofidelity’s Aspyre Lung is designed to run on existing qPCR platforms. It integrates seamlessly into laboratories worldwide.